Ceryvyn Therapeutics Limited CYVNY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 600.00 | 900.00 | 1.20K | 13.30K | 25.70K |
| Total Other Revenue | -- | -4.20K | -8.30K | 57.50K | 125.20K |
| Total Revenue | 600.00 | -3.20K | -7.00K | 70.90K | 151.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 600.00 | -3.20K | -7.00K | 70.90K | 151.00K |
| SG&A Expenses | 6.49M | 12.74M | 18.86M | 24.72M | 30.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 115.90K | 649.50K | 1.17M | 1.17M | 1.17M |
| Total Operating Expenses | 8.06M | 41.74M | 74.73M | 115.23M | 156.95M |
| Operating Income | -8.06M | -41.75M | -74.74M | -115.16M | -156.80M |
| Income Before Tax | 215.95M | 202.91M | 190.13M | 10.02M | -171.67M |
| Income Tax Expenses | -149.40K | -526.70K | -896.30K | -3.93M | -7.05M |
| Earnings from Continuing Operations | 216.10 | 203.43 | 191.03 | 13.95 | -164.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 216.10M | 203.43M | 191.03M | 13.95M | -164.62M |
| EBIT | -8.06M | -41.75M | -74.74M | -115.16M | -156.80M |
| EBITDA | -8.05M | -41.74M | -74.73M | -115.15M | -156.79M |
| EPS Basic | 0.16 | 0.15 | 0.14 | 0.00 | -0.13 |
| Normalized Basic EPS | 0.10 | 0.09 | 0.09 | 0.00 | -0.09 |
| EPS Diluted | 0.16 | 0.15 | 0.14 | 0.00 | -0.13 |
| Normalized Diluted EPS | 0.10 | 0.09 | 0.09 | 0.00 | -0.09 |
| Average Basic Shares Outstanding | 5.40B | 5.26B | 5.12B | 5.01B | 4.90B |
| Average Diluted Shares Outstanding | 5.40B | 5.26B | 5.12B | 5.01B | 4.90B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |